A Phase 1, Open-label, Dose-escalation Study of SNX 5422 and Everolimus in Subjects With Neuroendocrine Tumors.
Phase of Trial: Phase I
Latest Information Update: 04 Aug 2018
Price : $35 *
At a glance
- Drugs Everolimus (Primary) ; SNX 5422 (Primary)
- Indications Neuroendocrine tumours
- Focus Adverse reactions
- Sponsors Esanex
- 26 Jul 2018 Status changed from active, no longer recruiting to completed.
- 27 Feb 2018 Planned End Date changed from 1 Oct 2017 to 31 Mar 2018.
- 25 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Oct 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History